All In Biotech

NDA 217186 · Impax

Crexont

Carbidopa, Levodopa · Oral · Aromatic Amino Acid

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Aug 7, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

262

53 Phase 3, 16 recruiting

FAERS reports

5,848

3,390 serious, 622 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 29, 2026.

CREXONT is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults. CREXONT is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults. ( 1 )

Mechanism: Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa treats symptoms of Parkinson's disease.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • CREXONT · CARBIDOPA 70MG; LEVODOPA 280MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • CREXONT · CARBIDOPA 35MG; LEVODOPA 140MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • CREXONT · CARBIDOPA 87.5MG; LEVODOPA 350MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • CREXONT · CARBIDOPA 52.5MG; LEVODOPA 210MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbidopa" as an intervention, any sponsor and status, largest first.

All 262 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective659
  • fall514
  • hallucination512
  • dyskinesia443
  • tremor386
  • nausea317
  • dizziness306
  • death296
  • fatigue281
  • gait disturbance275
  • cough270
  • parkinson^s disease263

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200496
200592
200685
2007107
2008224
2009122
2010150
2011141
2012134
201331
201467
2015121
2016192
2017408
2018380
2019293
2020418
2021299
2022272
2023194
2024310
20251,044
2026668

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Crexont (Carbidopa/Levodopa)

2024 spending

$2.5M

Beneficiaries

1,825

2,918 claims

Per beneficiary

$1,365

$4.22 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$2,491,021

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 545 on PubMed

Sponsor: Impax

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.